	US 12,325,864 B2
	Recombinant virus vector (RVV) for inhibiting epidermal growth factor receptor (EGFR) activity and method of making an agent/target cell complex to increase cetuximab-like protein (CLP) production
Bradley G. Thompson, Calgary (CA)
Assigned to Kinase Pharma Inc., Calgary (CA)
Filed by Kinase Pharma Inc., Calgary (CA)
Filed on Jan. 24, 2023, as Appl. No. 18/158,852.
Application 18/158,852 is a continuation of application No. 17/313,801, filed on May 6, 2021, granted, now 11,603,541.
Prior Publication US 2023/0340533 A1, Oct. 26, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/86 (2006.01); A61K 48/00 (2006.01); C07K 16/28 (2006.01)

CPC C12N 15/86 (2013.01) [C07K 16/2863 (2013.01); A61K 48/00 (2013.01); C07K 2317/24 (2013.01); C12N 2330/50 (2013.01); C12N 2750/14143 (2013.01)]

5 Claims

1. A recombinant virus vector (RVV), the RVV comprising

a nucleotide sequence encoding for production of a cetuximab-like protein (CLP), wherein the nucleotide sequence comprises SEQ ID No: 1, SEQ ID No: 2, SEQ ID No: 3, SEQ ID No: 4, SEQ ID No.5, SEQ ID No: 6, SEQ ID No. 7 and SEQ ID No. 8,

wherein the RVV is an adeno-associated virus vector and wherein the CLP can bind to and inhibit the activity of Epidermanl Growth Factor Receptor (EGFR).